Xeloda and Rectal discharge - a phase IV clinical study of FDA data

Summary:

Rectal discharge is found among people who take Xeloda, especially for people who are male, 50-59 old, have been taking the drug for 1 - 6 months.

The phase IV clinical study analyzes which people take Xeloda and have Rectal discharge. It is created by eHealthMe based on reports of 44,763 people who have side effects when taking Xeloda from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Nov, 11, 2022

44,763 people reported to have side effects when taking Xeloda.
Among them, 9 people (0.02%) have Rectal discharge.

What is Xeloda?

Xeloda has active ingredients of capecitabine. It is often used in colon cancer. eHealthMe is studying from 45,114 Xeloda users for its effectiveness, alternative drugs and more.

What is Rectal discharge?

Rectal discharge (discharge from rectum) is found to be associated with 586 drugs and 299 conditions by eHealthMe.

Number of Xeloda and Rectal discharge reports submitted per year:

Time on Xeloda when people have Rectal discharge *:

Gender of people who have Rectal discharge when taking Xeloda *:

female: 22.22 %
male: 77.78 %

Age of people who have Rectal discharge when taking Xeloda *:

Common drugs people take besides Xeloda *:

Common side effects people have besides Rectal discharge *:

Weakness: 5 people, 55.56%
Proctalgia (pain in the rectum): 5 people, 55.56%
Disease Progression: 4 people, 44.44%
Nausea And Vomiting: 3 people, 33.33%
Diarrhea: 3 people, 33.33%
Abdominal Pain Lower: 3 people, 33.33%
Palmar-Plantar Erythrodysaesthesia Syndrome (hand-foot syndrome): 3 people, 33.33%
Constipation: 3 people, 33.33%
Intestinal Obstruction: 2 people, 22.22%
Dysplasia (enlargement of an organ or tissue): 2 people, 22.22%

Common conditions people have *:

Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 2 people, 22.22%

* Approximation only. Some reports may have incomplete information.

Do you take Xeloda and have Rectal discharge?

Check whether Rectal discharge is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Pinto HP, Bhat RM, Shet D, Dandekeri S, "Compound mucocutaneous adverse effects of oral capecitabine in a patient", Indian dermatology online journal, 2014 Jan .
Kang SM, Baek JY, Hwangbo B, Kim HY, Lee GK, Lee HS, "A case of capecitabine-induced sarcoidosis", Tuberculosis and respiratory diseases, 2012 Mar .

Related studies

How severe was Rectal discharge and when was it recovered:

Rectal discharge in Xeloda

Expand to all the drugs that have ingredients of capecitabine:

Rectal discharge and drugs with ingredients of capecitabine

Alternative drugs to, pros and cons of Xeloda:

Xeloda (45,114 reports)

Common Xeloda side effects:

Diarrhea: 7,361 reports
Death: 5,181 reports
Fatigue (feeling of tiredness): 3,918 reports
Nausea and vomiting: 3,249 reports
Rashes (redness): 2,645 reports

Browse all side effects of Xeloda:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Rectal discharge treatments and more:

Rectal discharge (3,875 reports)

COVID vaccines that are related to Rectal discharge:

Common drugs associated with Rectal discharge:

Alli: 2,612 reports
Humira: 280 reports

All the drugs that are associated with Rectal discharge:

Rectal discharge (586 drugs)

Common conditions associated with Rectal discharge:

Weight loss: 433 reports
Crohn's disease: 313 reports
Weight decreased: 244 reports

All the conditions that are associated with Rectal discharge:

Rectal discharge (299 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on capecitabine (the active ingredients of Xeloda) and Xeloda (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.